Investor Sentiment (Inverted) -- 7/10
This dimension is inverted -- high bullish sentiment is a negative signal
(crowded trade), while bearish/skeptical sentiment is positive (contrarian opportunity).
ADSK presents a compelling contrarian setup: stock down 28% from highs near 52-week lows,
forward P/E compressed to 19x (anomalously cheap for a 14%+ organic grower with expanding
margins), and short interest surging +36% MoM. Yet management just delivered a beat-and-raise
Q4 (revenue +19%, billings +33%), guided FY2027 confidently, and articulated the most
forward-leaning AI commentary in the transcript set. The Starboard Value settlement provides
an activist catalyst for 45% operating margins by FY2028. Capped at 7 because consensus
remains Buy (31/7/0), there is no insider buying at lows, and GTM restructuring creates
near-term execution risk.
Weight: 15%
Price vs. 52-Wk High
-28%
$238 vs. $329 high | Near 52-wk lows
Forward P/E
19.2x
Cheapest in peer group (avg ~29x)
Short Interest Trend
+36% MoM
6.4M shares (~3.0% of float)
Consensus Target
~$361
52% upside | Range $246-$430
Management-street divergence: HIGH
| Topic | Management View | Street View | Assessment |
|---|---|---|---|
| Q4 FY2026 Results | Beat across all metrics -- billings +33%, revenue +19%, non-GAAP margins above high end. Raised FY2027 guide confidently | Multiple price target cuts post-Q4 (Stifel $375 to $285, Deutsche $375 to $330). Stock punished despite beat-and-raise | HIGH DIVERGENCE -- management executing, street discounting |
| AI Strategy and Moat | CEO: "Never been more confident." Three-pillar AI strategy (data, context, expertise). Proprietary 3D data creates defensible moat for agentic AI | ADSK perceived as limited AI exposure vs. "pure AI" stocks. Market rotating away from traditional software toward AI beneficiaries | HIGH DIVERGENCE -- most forward-leaning AI commentary yet |
| Margin Trajectory | FY2027 guide: 38.5-39% non-GAAP margins (broke 3yr plateau at 36%). Path to 41% by FY2029 with Starboard pushing 45% by FY2028 | 7% workforce reduction (1,000 employees) spooked investors. Restructuring seen as defensive rather than strategic | MODERATE DIVERGENCE -- street sees cost cuts, management sees margin expansion |
| GTM Restructuring | Sales force restructuring flagged and guided conservatively. "Prudence" embedded for near-term disruption. CFO gained "deep understanding" after first full year | Near-term billings disruption risk is primary bear case. If Q1 FY2027 misses on billings, further downside likely | MODERATE DIVERGENCE -- management guided for it, street fears it |
| Capital Allocation | Repurchased $1.4B in FY2026 (~50% of FCF). "Recent share price weakness triggered greater share repurchases" -- buying more at lows | Buybacks noted but not viewed as a strong positive signal given no discretionary insider buying at lows | MILD DIVERGENCE -- corporate buying aggressively, insiders neutral |
| Construction Cloud | Rebranded to Forma for Construction. Competitive displacements won. Three ENR Top 400 contractors adopted in Q4. AEC segment +22% | Macro/tariff uncertainty affecting AEC and manufacturing end markets. Construction cost inflation (+8-14%) weighing on sentiment | MODERATE DIVERGENCE -- street pricing in macro risk, missing product wins |
Key sentiment metrics
| Metric | Value | Signal |
|---|---|---|
| Price vs. 52-wk high | -28% | Bearish sentiment (positive for inverted) |
| Price vs. consensus target | 52% upside ($238 to $361) | Large gap = market skepticism |
| Forward P/E | 19.2x | Compressed for growth software (peer avg ~29x) |
| Short interest trend | +36% MoM (Feb 2026) | Rising bearish bets (positive for inverted) |
| Implied FCF yield | ~5.5% | $2.75B FCF / $50B market cap -- attractive |
| Analyst consensus | 31 Buy / 7 Hold / 0 Sell | Still positive -- limits inverted score |
| Insider activity | Neutral (routine only) | No discretionary buying or selling at lows |
| Activist involvement | Starboard settled (board seats Apr 2025) | Constructive catalyst for margin discipline |
| Technical indicators | 20 bearish / 6 bullish | Below 50-day ($245) and 200-day ($287) MAs |
| Fear and Greed Index | 39 (Fear) | Broad market fear supporting contrarian case |
Contrarian assessment
Best Contrarian Case for ADSK
Valuation anomaly: 19x forward P/E is cheapest in peer group
(BSY ~35x, PTC ~22x, TRMB ~30x, avg ~29x) for a company growing revenue 14%+
organically with expanding margins and accelerating FCF (+54%). The market is
treating ADSK like a low-growth value stock despite double-digit growth.
Beat-and-raise ignored: Q4 FY2026 beat on all metrics -- revenue
+19%, billings +33%, margins above guide, FCF $2.4B (+54%) -- yet the stock was
punished and price targets were cut. This is the textbook "worse-to-better"
divergence that inverted scoring rewards.
Starboard activist catalyst: Settlement added two independent
directors (Epstein, Simons) in April 2025. Clear margin roadmap to 45% by FY2028.
7% workforce reduction aligns with this pressure. Provides external enforcement
of capital discipline and a re-rating catalyst.
Aggressive buybacks at lows: $1.4B repurchased in FY2026 (~50%
of FCF). Management explicitly noted that "recent share price weakness triggered
greater share repurchases" -- putting corporate capital where conviction is.
Why Capped at 7 (Not 8-9)
Consensus still Buy (31/7/0): Not a truly hated stock yet.
A score of 8-9 would require more Hold/Sell ratings and abandoned coverage.
The street has compressed targets but has not capitulated on the bull case.
No insider buying at lows: March 2026 transactions were entirely
routine PSU vesting and tax withholding. Last meaningful sale was COO Steven Blum
in Sept 2025. No discretionary open-market purchases -- a stronger contrarian
signal would require insiders putting personal capital to work.
GTM restructuring execution risk: Sales force restructuring
creates near-term billings disruption risk. If Q1 FY2027 (reported ~May 2026)
shows a significant billings miss, the stock could fall further. Management
guided conservatively for this, but execution is unproven.
Macro/tariff risk to end markets: AEC customers face construction
cost inflation (+8-14%) from tariffs. Manufacturing end markets have cyclical
exposure. These are real risks not fully within management control.
Score rationale
7/10 (Inverted) -- Strong contrarian setup
with meaningful management-street divergence. The stock is deeply out of favor with rising short
interest and compressing targets, yet management is delivering strong results and guiding
confidently with an activist enforcing margin discipline. The forward valuation at 19x is
anomalously low for this quality of business.
Positives: Stock down 28% from highs near 52-week lows -- deeply negative price
action. Short interest surged +36% MoM to 6.4M shares. Forward P/E of 19.2x is anomalously
compressed for a 14%+ organic grower with expanding margins. Beat-and-raise Q4 was punished by
the market. Multiple analyst price target cuts despite strong execution. Starboard settlement
provides activist catalyst for 45% margins by FY2028. Aggressive corporate buybacks at depressed
prices ($1.4B, ~50% of FCF). 5.5% implied FCF yield.
Negatives: Consensus remains Buy (31 Buy / 7 Hold / 0 Sell) -- not a truly hated stock yet. No discretionary insider buying at lows weakens the contrarian signal. GTM restructuring creates real near-term billings disruption risk for H1 FY2027. Macro/tariff risks to AEC end markets are genuine and not fully within management control. The 7% layoff, while potentially margin-accretive, adds execution risk.
The setup has genuine "worse-to-better" characteristics -- the market is pricing ADSK as a low-growth value stock while fundamentals are accelerating. However, the consensus has not fully capitulated, and the absence of insider buying prevents a higher score. The primary swing factor is Q1 FY2027 execution through the GTM restructuring.
Negatives: Consensus remains Buy (31 Buy / 7 Hold / 0 Sell) -- not a truly hated stock yet. No discretionary insider buying at lows weakens the contrarian signal. GTM restructuring creates real near-term billings disruption risk for H1 FY2027. Macro/tariff risks to AEC end markets are genuine and not fully within management control. The 7% layoff, while potentially margin-accretive, adds execution risk.
The setup has genuine "worse-to-better" characteristics -- the market is pricing ADSK as a low-growth value stock while fundamentals are accelerating. However, the consensus has not fully capitulated, and the absence of insider buying prevents a higher score. The primary swing factor is Q1 FY2027 execution through the GTM restructuring.